Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    TILT-123

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05222932
Recruitment Status : Not yet recruiting
First Posted : February 3, 2022
Last Update Posted : February 3, 2022
Sponsor:
Information provided by (Responsible Party):
TILT Biotherapeutics Ltd.

Brief Summary:
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.

Condition or disease Intervention/treatment Phase
Melanoma Head and Neck Squamous Cell Carcinoma Biological: TILT-123 Drug: Avelumab Phase 1

Detailed Description:
This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 TILT-123 in combination with avelumab in patients with advanced solid tumors (SCCHN and melanoma) refractory to or progressing after anti-PD(L)1. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial is conducted in Helsinki (Finland).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open-label, single arm, dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and IL-2 Coding Oncolytic Adenovirus TILT-123 and Avelumab in Solid Tumor Patients (Melanoma and SCCHN) Refractory to or Progressing After Anti-PD(L)1
Estimated Study Start Date : March 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2026


Arm Intervention/treatment
Experimental: TILT-123 and avelumab

Patients will receive multiple administrations of TILT-123 and avelumab.

Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level.

Biological: TILT-123
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
Other Names:
  • TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
  • Ad5/3-E2F-d24-hTNFa-IRES-hIL2

Drug: Avelumab
Anti-PDL1 antibody
Other Name: anti-PD-L1 monoclonal antibody




Primary Outcome Measures :
  1. Number of Participants with any (serious and non-serious) Adverse Events. [ Time Frame: 85 days ]
    Safety I

  2. Number of Participants with abnormal laboratory values. [ Time Frame: 85 days ]
    Safety II

  3. Number of Participants with vital sign abnormalities. [ Time Frame: 85 days ]
    Safety III

  4. Number of Participants with Adverse Events assessed by 12- lead electrocardiograms (ECGs) [ Time Frame: 85 days ]
    Safety IV



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject must be over 18 years of age
  2. Subject must have pathologically confirmed refractory or recurrent injectable solid tumor (melanoma or SCCHN), which cannot be treated with curative intent with available therapies and is refractory to or progressing after anti-PD(L)1 immunotherapy.
  3. Standard therapy has failed, it does not exist, is not available or is unlikely to result in meaningful clinical benefit (as assessed by the investigator). Multiple prior therapies (eg. surgery, chemotherapy, radiation, checkpoint inhibitors, kinase inhibitors, biological therapies) are allowed.
  4. At least one tumor lesion of 15 mm or bigger must be available for biopsy and injections that, in the opinion of the investigator, is accessible to repeated injections and biopsies without major safety concerns.
  5. The disease burden must be evaluable, but does not need to fulfil RECIST 1.1
  6. Patients must have received at least 6 weeks of prior PD-1/PDL-1 blocking antibody therapy (e.g. 3x 2w cycle or 3x 3w cycle) within the past up to 6 months
  7. Patients must have experienced unequivocally documented radiographic progression of disease during or within 6 weeks after the last dose of such treatment.
  8. Subject must have adequate hepatic and renal functions, including the following laboratory parameters:

    1. Platelets > 75 000/mm3
    2. Haemoglobin ≥ 100 g/L.
    3. AST and ALT < 3 x ULN.
    4. GFR >60 ml/min (Cockcroft-Gault formula).
    5. Leukocytes (WBC) > 3,0
    6. Bilirubin <1,5 x ULN
  9. Men and women must be willing to use adequate forms of contraception from screening, during the trial, and for a minimum of 90 days after end of treatment, in accordance with the following:

    1. Women of childbearing potential: Barrier contraceptive method (i.e. condom) must be used in addition to one of the following methods: Intrauterine device or hormonal contraception (oral contraceptive pills, implant, transdermal patches, vaginal ring or long-acting injections).
    2. Women not of childbearing potential: Barrier contraceptive method (i.e. condom) must be used.
    3. Men: Barrier contraceptive method (i.e. condom) must be used.
  10. Subject must demonstrate a WHO/ECOG performance score of 0-1
  11. Subject must have life expectancy longer than 3 months according to investigator assessment
  12. Subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent approved by the Independent Ethics committee prior to the initiation of any screening or study -specific procedure.

Exclusion Criteria:

  1. Prior organ transplantation including allogenic stem-cell transplantation or subject is using systemic immunosuppressive medications (eg. corticosteroids or drugs used in treatment of autoimmune disease). Exempted are the following which can be allowed at screening and during the trial: a) replacement corticosteroids if e.g. the patient has adrenal insufficiency after prior immunotherapy b) inhaled and topical treatments c) up to 20 mg/d of prednisone/prednisolone (or equivalent).
  2. Treated with any anti-cancer therapy within 30 days prior to the first virus injection. Anti-cancer therapy is defined as anti-cancer agents (e.g. cytotoxic chemotherapy, immunotherapy, signal-transduction inhibitors, biological therapies) and investigational agents. An investigational agent is any drug or therapy that is currently not approved for use in humans. Continuation of bone modifying agents (eg. bisphosphonate or denosumab) is allowed if started at least 3 months before. Palliative radiation is not allowed within 14 days of the first virus injection (before or after), but it is allowed after day 15 during the trial treatment period, if deemed necessary by the investigator.
  3. Subject has a history of another active invasive cancer within the past 5 years, except curatively treated basalioma or squamous cell carcinoma of the skin
  4. Clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  5. Subject has a history of interstitial parenchymal lung disease.
  6. Subject has a LDH value > 3 x ULN (melanoma)
  7. Subject has a history of severe hepatic dysfunction, hepatitis, HIV or other severe chronic but active infectious diseases requiring systemic therapy, e.g. tuberculosis
  8. Subject is using proton pump inhibitors or antibiotics during screening period
  9. Subject has a history of a coagulation disorder or abnormality in coagulation parameters, as defined by an international normalized ratio not within the normal range, or has received oral or parenteral anticoagulants or thrombolytic agents for therapeutic or prophylactic purposes (including coumadin and warfarin) within 10 days of the first dose of the study treatments. Low molecular weight heparin is permitted if the international normalized ratio is within the normal range
  10. Any other medical condition or laboratory abnormality that in the judgment of the principal investigator, may increase the risk associated with study participation or may interfere with interpretation of study results and /or otherwise make the patient inappropriate for entry into this trial.
  11. Subject is pregnant, breastfeeding or intend to become pregnant
  12. Subject has untreated brain metastases. Treated and asymptomatic brain metastases which have not progressed in 3 months prior to study entry are allowed.
  13. Any known or suspected allergy to TILT-123 or ingredients present in the drug product as listed in this protocol.
  14. Any known or suspected allergy to avelumab or ingredients present in the drug product as listed in summary of product characteristics (SmPC), including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE Grade ≥ 3).
  15. Known current alcohol or drug abuse
  16. Vaccination with live vaccines in the past 30 days prior to start of investigational treatment
  17. History of immune-related adverse events to previous immunotherapy which led to discontinuation from treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05222932


Locations
Layout table for location information
Finland
Docrates Cancer Center
Helsinki, Finland, 00180
Contact: Tuomo Alanko    +358 107732050    hospital@docrates.com   
Principal Investigator: Tuomo Alanko, MD, PhD         
Sponsors and Collaborators
TILT Biotherapeutics Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Tuomo Alanko Docrates Cancer Center
Layout table for additonal information
Responsible Party: TILT Biotherapeutics Ltd.
ClinicalTrials.gov Identifier: NCT05222932    
Other Study ID Numbers: T776
First Posted: February 3, 2022    Key Record Dates
Last Update Posted: February 3, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by TILT Biotherapeutics Ltd.:
oncolytic virus
immunotherapy
immune checkpoint inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Squamous Cell Carcinoma of Head and Neck
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Head and Neck Neoplasms
Neoplasms by Site
Avelumab
Antineoplastic Agents, Immunological
Antineoplastic Agents